source
- Superluminal Medicines raises $60 million to advance AI-designed MC4R drug for rare obesity formsSuperluminal Medicines, an AI-driven drug discovery startup, announced a $60 million financing round aimed at moving its first candidate toward clinical testing. The candidate targets the MC4R G p…
- GSK to spend up to $1.3 billion on Hutchmed's dual-target cancer therapyGSK announced a deal to acquire the majority rights to Hutchmed's experimental therapy HMPL-A830. The agreement includes an upfront payment of $110 million and potential milestone and royalty payme…